Category Archives: Orphan Drugs
By Guest Blogger | Published: May 12, 2014
by Matthew Cook and Sebastien Morisot In light of the risks and challenges inherent in the development of oncologics, some biopharma companies are beginning to question whether oncology remains an attractive therapeutic area in which to invest limited research, development, and commercialization resources.
By William Looney | Published: May 7, 2014
Pharm Exec’s Brand of the Year award is itself a brand with staying power — our first recipient was Merck’s Gardasil papillomavirus vaccine, which eight years later is still going strong as one of the company’s 10 top-selling products.
By Pharm Exec | Published: March 21, 2014
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for Sylvant (siltuximab) for adult patients with multicentric Castleman’s disease.
By Pharm Exec | Published: February 26, 2014
Swedish Orphan Biovitrum AB (Sobi) was last night presented with a EURORDIS Award for its commercial and development portfolio in the field of rare diseases. The award also recognized the company’s track record on access to drugs and its collaboration with patient organizations. EURORDIS is Europe’s largest patient organization in rare diseases. Its CEO, Yann […]
By Guest Blogger | Published: February 24, 2014
Next week Europe will celebrate Rare Disease Day. This is an interesting example – one might almost say a rare example – of a successful attempt by a European interest group to capture public attention. It is now an annual awareness-raising event co-ordinated by the European rare diseases lobby group, EURORDIS. For this year’s celebration, […]